$DVLT

Why is Datavault AI stock sliding today?

Datavault AI Inc. (DVLT) stock fell 10.3% pre-market to $0.347 after reporting a widened net loss of $18.36M in Q2 2026, with revenue far below its $200M annual goal. The company raised $25M via a convertible note and 15M shares, fueling dilution concerns, and faces a $94.5M acquisition amid cash shortages. Nasdaq delisting risk and a lawsuit also weigh on the stock.

Original reporting
Published Aug 19, 2026, 10:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DVLT
Bearish
high confidence
Mentioned
$DVLT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DVLTBearishHigh
01

Why it matters

The earnings miss and financing actions increase short‑term risk, but the acquisition could be a catalyst if executed.

02

Market read

The stock's steep pre‑market decline is driven by its own earnings and financing news, not broader market moves.

03

What to watch

Potential upside from Nasdaq bid‑price compliance if capital raise succeeds.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Datavault AI is a micro‑cap AI‑driven medtech company trading on Nasdaq.

Company-level read

Ticker impact

$DVLTBearishHigh confidence
Context

Q2 2026 results showed a widened net loss of $18.36M and a 10.3% pre‑market slide.

Expected impact

Further downside pressure in intraday trading.

Evidence & confidence

Loss expansion, debt extinguishment cost, and dilution raise capital adequacy concerns.

Market effects

Highlights financing challenges for micro‑cap AI medtech firms.

Limited to US small‑cap investors.

Minimal beyond niche AI/medtech sector.

Counterpoint

If the acquisition of CyberCatch delivers strategic value, the stock could rebound.

Key entities

  • Datavault AI Inc.

    AI‑focused medtech firm reporting Q2 2026 results.

  • Streeterville Capital

    Provider of a $25M convertible note and 15M shares.

  • CyberCatch Holdings

    Proposed $94.5M cash acquisition target.

Related articles

$DVLTHigh

Datavault AI Moves to Add Banking Arm With BankWyse Deal

Datavault AI (DVLT) agreed to acquire BankWyse, a Wyoming-chartered bank, to add custody and banking services to its digital-asset platform. The deal, pending regulatory approval, supports DVLT's strategy of vertical integration in digital and real-world asset markets. Financial terms were not disclosed.

$DVLTHighAI 8/10

DataVault AI (DVLT) Q2 2026 Earnings Call Transcript

DataVault AI (DVLT) reported Q2 2026 revenue of $6.7M, up 287% YoY. The company reiterated its $200M full-year revenue target, driven by Acoustics Group and medical licensing. It has $2.5B in signed tokenization contracts, with $213M in potential fees. Management highlighted acquisitions, regulatory challenges, and a strong balance sheet. Q2 net loss was $88M, with gross profit of $2.9M.

$DVLTMed

August 25, 2026 - 8-K: Current report

Datavault AI Inc. (DVLT) received a 180-day extension from Nasdaq to comply with the $1 minimum bid price requirement, now due by February 22, 2027. The company previously failed to meet this requirement by the initial deadline of August 24, 2026. DVLT's stock continues to trade on the Nasdaq Capital Market under the symbol 'DVLT' during this period.

HighAI 9/10

Datavault AI Inc. Q2 2026 Earnings Call Summary

Datavault AI Inc. reiterated its $200M revenue target for 2026, driven by its Data Science and Acoustic Science divisions. The company announced partnerships, acquisitions, and a $150M stock conversion to enhance its balance sheet. It plans to launch exchanges in mid-September 2026 and anticipates significant revenue growth in Q4, supported by $213M in signed contract fees. The company aims to avoid a reverse stock split by meeting revenue guidance and leveraging a shareholder equity exemption.